Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

FROM:

BIVICTRIX THERAPEUTICS PLC

Ticker: BVX

Description

BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.
READ MORE >

Company Snapshot

COMPANY INSIGHTS

Trading Results

DateQuantityMid. Price GBX
30/09/20245000011.50
16/09/2024100,00011.00
16/09/2024150,00011.00

key features of trading on jp jenkins

BUYERS
Buyers decide on the price per share they’re willing to pay, and the number of shares they wish to buy.

SELLERS
Sellers decide the minimum price they’ll accept for their shares.

IMPORTANT INFORMATION
This instruments from BIVICTRIX THERAPEUTICS PLC is not traded on an investment exchange such as the London Stock Exchange or the Alternative Investment Market. Consequently, transactions involving these instruments may be infrequent, potentially causing a delay between when you give instructions to buy or sell and when your order is executed. Additionally, it can be challenging to accurately assess the value of your investment.

Description

BiVictriX Therapeutics Ltd (“BVX”) is an emerging biotechnology company leveraging clinical experience and its proprietary discovery engine to advance a new class of highly cancer-selective, next-generation precision cancer therapies in one of the fastest-growing markets in oncology. BiVictriX’s first-in-class Bi-Cygni® bispecific Antibody Drug Conjugates (“ADCs”) combine superior efficacy with substantially improved cancer-selectivity and safety to provide opportunities for prolonged dosing and greater efficacy in the clinic. The Company is advancing its pipeline to deliver the future of cancer care across a broad range of haematological and solid cancer indications in areas of high unmet medical need.
READ MORE >

Want to keep up to date
with our companies?

BIVICTRIX THERAPEUTICS PLC Management Information

Tiffany Thorn
Tiffany Thorn
Chief Executive Officer
Dr Michael Kauffman
Dr Michael Kauffman
Non-Executive Chairman
Prof. Robert Hawkins
Prof. Robert Hawkins
Independent Non-Executive Director
Susan Lowther
Susan Lowther
Independent Non-Executive Director
Drummond Paris
Drummond Paris
Senior Independent Non-Executive Director

BIVICTRIX THERAPEUTICS PLC Contact Details

Address
Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG
EMAIL
info@bivictrix.com
phone
Contacts
Registrar
Share Registrars Limited
The Courtyard
17 West Street
Farnham
Surrey GU9 7DR

TRANSACTING ON JP JENKINS

‘Trading on JP Jenkins is done via a matched bargain facility, this means that on instruction from your ‘Broker’ we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you

How to Trade

Trading with JP Jenkins

Trading Instructions:
To buy and sell shares in this company via JP Jenkins, you will need to use a regulated UK stockbroker.

For a comprehensive list of brokers click here.

Over 40 UK brokers regularly trade and are set up to deal on our platform.
If you are based overseas and are interested in participating then please contact us directly by emailing info@jpjenkins.com or by calling 0207 469 0937
When buying or selling shares, please note there is as 1.5% trading fee (with a minimum charge of £25) (*additional fees may apply).

Please note, when purchasing shares Stamp Duty Reserve Tax (“SDRT”) may be applicable.

Trading with JP Jenkins